Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M215,186Revenue $M51,432Net Margin (%)17.6Altman Z-Score3.6
Enterprise Value $M225,645EPS $1.3Operating Margin %27.4Piotroski F-Score5
P/E(ttm)23.9Beneish M-Score-2.9Pre-tax Margin (%)23.8Higher ROA y-yN
Price/Book10.010-y EBITDA Growth Rate %--Quick Ratio0.9Cash flow > EarningsY
Price/Sales4.25-y EBITDA Growth Rate %1.5Current Ratio1.2Lower Leverage y-yY
Price/Free Cash Flow19.0y-y EBITDA Growth Rate %-1.7ROA % (ttm)12.1Higher Current Ratio y-yN
Dividend Yield %3.2PEG15.9ROE % (ttm)46.1Less Shares Outstanding y-yY
Payout Ratio %74.0Shares Outstanding M6,816ROIC % (ttm)30.4Gross Margin Increase y-yN

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYKen Fisher 2016-03-31 Add0.02%$30.09 - $34.47
($31.91)
$ 31.57-1%Add 1.88%14,906,191
RHHBYKen Fisher 2015-12-31 Add0.01%$32.55 - $35.08
($33.69)
$ 31.57-6%Add 0.63%14,630,453
RHHBYKen Fisher 2015-09-30 Add0.02%$31.65 - $36.87
($34.69)
$ 31.57-9%Add 2.30%14,538,602
RHHBYKen Fisher 2015-06-30 Add0.8%$34.38 - $38.46
($36.09)
$ 31.57-13%Add 409.71%14,211,412
RHHBYKen Fisher 2015-03-31 Reduce$32.1 - $36.505
($34.06)
$ 31.57-7%Reduce -1.24%2,788,126
RHHBYKen Fisher 2014-12-31 Add0.07%$34.16 - $37.92
($36.33)
$ 31.57-13%Add 49.26%2,823,025
RHHBYKen Fisher 2014-06-30 Reduce-0.07%$35.42 - $38.07
($36.82)
$ 31.57-14%Reduce -49.71%1,813,443
RHHBYKen Fisher 2014-03-31 Add0.07%$18.14 - $38.17
($29.75)
$ 31.576%Add 99.00%3,606,140
RHHBYKen Fisher 2013-12-31 Reduce$31.96 - $35.24
($34.16)
$ 31.57-8%Reduce -0.26%1,812,112
RHHBYKen Fisher 2013-09-30 Add$30.66 - $33.77
($31.84)
$ 31.57-1%Add 0.28%1,816,868
RHHBYKen Fisher 2013-06-30 Add$28.92 - $32.98
($30.95)
$ 31.572%Add 0.90%1,811,804
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.95)
$ 31.572%Sold Out0
RHHBYKen Fisher 2013-03-31 Add0.12%$25.25 - $29.3
($27.75)
$ 31.5714%Add 634.57%1,795,722
RHHBYTweedy Browne 2012-12-31 Reduce$23.08 - $25.68
($24.53)
$ 31.5729%Reduce -3.04%120,548
RHHBYKen Fisher 2012-12-31 Reduce$23.08 - $25.68
($24.53)
$ 31.5729%Reduce -14.81%244,460
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.99 - $24.07
($22.49)
$ 31.5740%Reduce -24.31%124,328
RHHBYKen Fisher 2012-09-30 Reduce$20.99 - $24.07
($22.49)
$ 31.5740%Reduce -7.27%286,946
RHHBYVanguard Health Care Fund 2012-06-30 Add2.96%$19.43 - $23.14
($21.16)
$ 31.5749%Add 543.36%8,547,954
RHHBYKen Fisher 2012-06-30 Reduce-0.01%$19.43 - $23.14
($21.16)
$ 31.5749%Reduce -24.26%309,426
RHHBYKen Fisher 2012-03-31 Reduce-1.27%$20.89 - $22.5
($21.77)
$ 31.5745%Reduce -98.02%408,552
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RHHBY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about RHHBY:

    News about RHHBY:

    Articles On GuruFocus.com
    Bearish Sentiment in Becton Dickinson's Stock Apr 27 2016 
    Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
    Invesco European Growth Fund Adds to More Than 40 Existing Stakes Apr 04 2016 
    Invesco European Growth Fund Adds to 7 Stakes Jan 26 2016 
    Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 
    Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
    Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
    UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
    It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
    Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 

    More From Other Websites
    [$$] AstraZeneca's Investment Eats Into Profit Apr 29 2016
    Sanofi Presses Medivation to Hold Talks After $9.3B Offer Apr 28 2016
    Moody's: Global pharmaceutical growth will remain steady despite cost containment efforts Apr 26 2016
    Does Biotech’s Recent Bounce Have Legs? Apr 22 2016
    Roche (RHHBY) Beats on Q1 Sales, New Launches in Focus (revised) Apr 21 2016
    [$$] Roche Revenue Lifted by Cancer and Immunology Drugs Apr 19 2016
    [$$] 4 Stocks Growing Smartly, But Trading at a Discount Apr 19 2016
    [$$] Roche 'very optimistic' on prospects for new cancer drugs Apr 19 2016
    Roche sales set hard challenge for drug industry rivals Apr 19 2016
    Cancer Meds Help Roche Beat 1Q Sales Apr 19 2016
    Cancer Meds Help Roche Beat 1Q Sales Apr 19 2016
    Roche Sees Its First Cancer Immunotherapy Winning U.S. Nod Soon Apr 19 2016
    Genentech to Present New Data at AAN Showing Superior Efficacy of Investigational Medicine... Apr 12 2016
    Roche/AbbVie's Lymphocytic Leukemia Drug Gets FDA Nod Apr 12 2016
    Genentech Announces FDA Grants Venclexta™ (venetoclax) Accelerated Approval for People With a... Apr 11 2016
    Roche's Lung Cancer Candidate Gets Priority Review in U.S. Apr 11 2016
    AbbVie/Roche drug gets U.S. approval for a rare type of leukemia Apr 11 2016
    FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of... Apr 11 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)